secwatch.observer — SEC 8-K summary
======================================

Issuer:     SHINECO, INC. (—)
CIK:        0001300734
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001493152-23-000231
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shineco completes acquisition of 51% of Changzhou Biowin Pharmaceutical for $9M cash + 3.26M shares
--------------------------------------------------------------------------------

- Total consideration ~$12.1M: $9M cash plus 3.26M SISI shares valued at $0.95/share (~$3.1M).
- Acquisition closed Dec 30, 2022; subsidiary Shineco Life Science Research acquired 51% stake from Beijing Kanghuayuan.
- Performance targets for 2023-2025: 2023 rev >=RMB35M, net profit >=RMB5.5M; 2024 rev >=RMB50M, net profit >=RMB10M; 2025 rev >=RMB80M, net profit >=RMB20M.
- Financial statements of Biowin to be filed by amendment within 71 days of 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1300734/000149315223000231/0001493152-23-000231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1300734/000149315223000231/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-000231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer